NEW YORK (GenomeWeb News) - Invitrogen said today that it has licensed an engineered neural stem cell line from the Buck Institute for Age Research.
 
Invitrogen said that the stem cell line, BG01 Olig2-GFP, has been engineered to track the Olig2 gene, which controls a protein that maintains a neural stem cell's ability to replicate early in brain development, and then directs it to form a particular type of neural cell.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.